Skip to main content
. 2014 Mar 20;2014:137304. doi: 10.1155/2014/137304

Table 5.

Overall survival rates categorized by HER2 status and adjuvant therapy.

3-year OS 5-year OS 6-year OS 7-year OS
HER2 positive
 Trastuzumab + CHT+ AHT 97% 96% 96% 96%
 CHT + AHT 98% 98% 92% 92%
 Trastuzumab + CHT 95% 92% 92% 86%
 CHT 82% 65% 65% 65%
 AHT 91% 83% 79% 79%
 No adjuvant therapy 75% 63% 55% 55%
HER2 negative
 CHT + AHT 98% 95% 93% 92%
 CHT 89% 86% 83% 83%
 AHT 95% 90% 88% 88%
 No adjuvant therapy 81% 75% 73% 64%